Fear Blurs Danger and Safety in the Brain
A Nature Neuroscience paper shows how overlapping fear and safety memories in mice speed up their reactions to danger.
Global Alzheimer's News
Coverage here follows Alzheimer's disease and dementia — research advances, drug approvals, clinical trial findings, caregiving policy and the risk factor studies that describe what is known about prevention and progression. Reporting draws on peer-reviewed science and the regulatory and policy responses it generates.
Recent news
November 7, 2026
Acumen Halts Sabirnetug Alzheimer's Drug DevelopmentThe Phase 2 trial of the antibody sabirnetug failed to show clinical benefit, prompting Acumen Pharmaceuticals to stop commercial development.
November 7, 2026
UNESCO Honors Nancy Ip for Alzheimer's ResearchThe international life sciences prize recognizes Ip's biomarker discoveries and blood tests aimed at earlier Alzheimer's diagnosis.
November 6, 2026
Skull Marrow Drives Brain Inflammation After InjuryA study of 41 participants and a randomized trial link aging, cranial bone marrow activity, and cognition in chronic traumatic brain injury.
November 6, 2026
Anxiety Linked to Greater Pain in Parkinson'sA cross-sectional study of 100 patients found anxiety severity consistently tracked with pain in Parkinson's disease.
November 6, 2026
Claustrum Helps Hold Working Memory in MiceA study from UNIGE found that disrupting claustrum neuron activity cut working memory performance in mice by half.
November 6, 2026
Azer-cel Shows Safety in Progressive MS TrialA phase I study of an off-the-shelf CAR T cell therapy found no serious dose-related adverse events in 18 adults with progressive multiple sclerosis.
November 6, 2026
Obesity Drugs May Protect Brain, Review FindsA Science review by Swedish and Danish researchers weighs mixed evidence on GLP-1 drugs and cognition.
November 5, 2026
Speech Clock Estimates Biological Age From VoiceA new machine-learning tool analyzes speech patterns to compare biological age with chronological age in people with cognitive decline.
November 5, 2026
Meta-Analysis Maps Brain Genes Tied to EnrichmentResearchers combined findings from more than 300 rodent studies to identify synapse-related gene patterns linked to environmental enrichment.
November 5, 2026
Experts Urge G20 to Prioritize Alzheimer's CareFormer ministers and global health leaders call on the G20 to make brain health a standing policy priority.
More in Alzheimer’s
This section follows drug approval proceedings and the clinical trial data behind them, caregiving burden research, diagnosis guideline updates, risk factor studies, funding decisions for dementia research and the advocacy and awareness campaigns that accompany major findings. Drug approvals for Alzheimer's have become among the most closely watched regulatory proceedings in medicine, since the disease's prevalence and the absence of effective treatments for decades made each candidate a subject of sustained public attention. Caregiving coverage runs alongside the clinical and research reporting, since the burden on family caregivers is large enough to constitute a public health and economic story in its own right. Early detection and biomarker research have shifted some Alzheimer's coverage toward prevention and risk management, producing a reporting track that reaches people who are not patients and may not become them.